ICU Medical Q4 2024 Earnings Report
Key Takeaways
ICU Medical's Q4 2024 revenue rose to $629.8 million, reflecting strong demand across all segments, particularly in Vital Care. However, the company posted a GAAP net loss of $23.8 million, with an EPS of $(0.97), impacted by increased operating expenses. Adjusted EPS improved to $2.11, and adjusted EBITDA grew to $105.5 million, driven by better gross margins and higher revenue.
Total revenue increased 7.1% year-over-year to $629.8 million.
GAAP net loss widened to $23.8 million from $17.1 million in Q4 2023.
Adjusted EPS improved to $2.11 from $1.57 in Q4 2023.
Adjusted EBITDA grew to $105.5 million from $86.3 million last year.
ICU Medical Revenue
ICU Medical EPS
ICU Medical Revenue by Segment
Forward Guidance
ICU Medical expects revenue and profitability growth in FY 2025, driven by strong demand and operational efficiency improvements.
Positive Outlook
- Projected adjusted EPS between $6.55 and $7.25.
- Adjusted EBITDA expected to be in the range of $395M to $425M.
- Strong demand expected for IV solutions and infusion systems.
- Operational efficiencies anticipated to improve gross margins.
- Continued focus on cost reductions and integration synergies.
Challenges Ahead
- GAAP net loss expected between $45M and $28M for FY 2025.
- Potential impact from the IV Solutions joint venture reducing adjusted EBITDA by $15M to $20M.
- Higher restructuring and integration costs projected at $43M.
- Regulatory and quality system initiatives expected to cost $50M.
- Interest expense projected to remain high at $95M.
Revenue & Expenses
Visualization of income flow from segment revenue to net income